> Detailanzeige

Pfaar, Oliver; Agache, Ioana; de Blay, Frédéric; Bonini, Sergio; Chaker, Adam M.; Durham, Stephen R.; Gawlik, Radoslaw; Hellings, Peter W.; Jutel, Marek; Kleine‐Tebbe, Jörg; Klimek, Ludger; Kopp, Matthias V.; Nandy, Andreas; Rabin, Ronald L.; van Ree, Ronald; Renz, Harald; Roberts, Graham; Salapatek, Anne‐Marie; Schmidt‐Weber, Carsten B.; Shamji, Mohamed H.; Sturm, Gunter J.; Virchow, J. Christian; Wahn, Ulrich; Willers, Christoph; [...]

Perspectives in allergen immunotherapy: 2019 and beyond

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Perspectives in allergen immunotherapy: 2019 and beyond
  • Beteiligte: Pfaar, Oliver; Agache, Ioana; de Blay, Frédéric; Bonini, Sergio; Chaker, Adam M.; Durham, Stephen R.; Gawlik, Radoslaw; Hellings, Peter W.; Jutel, Marek; Kleine‐Tebbe, Jörg; Klimek, Ludger; Kopp, Matthias V.; Nandy, Andreas; Rabin, Ronald L.; van Ree, Ronald; Renz, Harald; Roberts, Graham; Salapatek, Anne‐Marie; Schmidt‐Weber, Carsten B.; Shamji, Mohamed H.; Sturm, Gunter J.; Virchow, J. Christian; Wahn, Ulrich; Willers, Christoph; [...]
  • Erschienen: Wiley, 2019
  • Erschienen in: Allergy, 74 (2019) S108, Seite 3-25
  • Sprache: Englisch
  • DOI: 10.1111/all.14077
  • ISSN: 0105-4538; 1398-9995
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractThe seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the “Therapy Allergen Ordinance” in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.
  • Zugangsstatus: Freier Zugang